( fficacy (lackof acute rejection) wit...)Isotechnika's independent data monitoring committee conducts review,,,of phase 2b kidney transplant trial,Health

fficacy (lack of acute rejection) with minimal side effects that are typically seen with other calcineurin inhibitors such as cyclosporine and tacrolimus. A total of 332 de novo (newly transplanted) kidney transplant patients will be enrolled in this trial. Patients will be placed into one of four separate treatment groups; three different dose groups of ISA247 (0.4 mg/kg, 0.6 mg/kg, and 0.8 mg/kg twice daily compared with the fourth group, a tacrolimus (0.05 mg/kg twice daily) control arm. Patients in all four treatment groups will have their doses adjusted in order to achieve pre-defined blood levels of either ISA247 or tacrolimus. All patients will receive oral treatment of drug (ISA247 or tacrolimus) over a six month period along with other standard immunosuppressive therapies used following transplantation.

About Isotechnika -----------------

Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies. Isotechnika's lead compound, ISA247 has successfully completed a Phase 3 Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is currently being investigated in a combined Phase 3 European/Canadian psoriasis trial and a Phase 2b North American trial for the prevention of kidney graft rejection. Our partner, Lux Biosciences has received permission from the Food and Drug Administration to investigate IS
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
8. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
9. Ad hoc: Interim report about clinical trial of BF-200 ALA in actinic keratosis
10. Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404